WallStSmart
ADMA

ADMA Biologics Inc

NASDAQ: ADMA · HEALTHCARE · BIOTECHNOLOGY

$10.60
-2.75% today

Updated 2026-04-29

Market cap
$2.46B
P/E ratio
17.67
P/S ratio
4.83x
EPS (TTM)
$0.60
Dividend yield
52W range
$7 – $24
Volume
6.8M

ADMA Biologics Inc (ADMA) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-4.0%
Last 4 quarters
Revenue YoY growth
+18.4%
Most recent quarter
EPS YoY growth
+58.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-6.5%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-11.7%
2025-08-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-19$0.22+15.5%$14.87$14.32-3.7%
2025-11-05$0.15+0.0%$14.63$14.03-4.1%
2025-08-06$0.14-6.7%$18.96$16.75-11.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.19$0.22+15.5%$139.16M+18.4%
2025-09-30$0.15$0.15+0.0%$134.22M+12.0%
2025-06-30$0.15$0.14-6.7%$121.98M+13.8%
2025-03-31$0.15$0.11-25.0%$114.80M+40.2%
2024-12-31$0.15$0.14-6.2%$117.55M+59.1%
2024-09-30$0.13$0.15+15.4%$119.84M+78.1%
2024-06-30$0.08$0.13+62.5%$107.19M+78.3%
2024-03-31$0.06$0.08+33.3%$81.88M+43.9%
2023-12-31$0.03$-0.08-366.7%$73.90M
2023-09-30$-0.01$0.01+200.0%$67.28M
2023-06-30$-0.02$-0.03-50.0%$60.12M
2023-03-31$-0.04$-0.03+25.0%$56.91M

Frequently asked questions

Has ADMA Biologics Inc beaten earnings estimates?
ADMA Biologics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -4.0% over the last 4 quarters.
How does ADMA stock react to earnings?
ADMA stock has moved an average of -6.5% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is ADMA Biologics Inc's revenue growth rate?
ADMA Biologics Inc reported year-over-year revenue growth of +18.4% in its most recent quarter, with EPS growing +58.6% year-over-year.